Vineetha Raghavan
YOU?
Author Swipe
View article: Impact of the COVID‐19 pandemic on treatment of patients with acute myeloid leukaemia in India
Impact of the COVID‐19 pandemic on treatment of patients with acute myeloid leukaemia in India Open
During the COVID-19 pandemic, our findings highlight changes in AML management strategies in India. There was a decrease in overall patient registrations, particularly at large referral centers, while smaller centers saw an increase, refle…
View article: Treatment challenges and outcomes of older patients with acute myeloid leukemia from India
Treatment challenges and outcomes of older patients with acute myeloid leukemia from India Open
Globally, overall survival (OS) of older patients with AML continues to be suboptimal with very little data from India. In a multicenter registry analysis, we evaluated 712 patients with AML older than 55 years. Only 323 (45.3%) underwent …
View article: Patterns of Care and Outcome in Adolescent and Young Adults (AYA) Lymphomas- a Multicenter HCC (Hematologic Cancer Consortium) Registry Study from India
Patterns of Care and Outcome in Adolescent and Young Adults (AYA) Lymphomas- a Multicenter HCC (Hematologic Cancer Consortium) Registry Study from India Open
Introduction There are no recommendations pertaining to lymphoma in AYA population. It represents a paramount opportunity for fostering collaborative research among pediatric and medical oncologists. Prior to embarking on any collaborative…
View article: Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience Open
The coronavirus (COVID -19) pandemic posed critical challenges for public health, research, diagnosis, and treatment globally. Beyond the existing challenges in the management of Acute Myeloid Leukemia (AML) in India; we hypothesized that …
View article: Influence of blood transfusion during induction chemotherapy on treatment outcomes in acute myeloid leukemia
Influence of blood transfusion during induction chemotherapy on treatment outcomes in acute myeloid leukemia Open
BACKGROUND: Transfusion is an integral part of supportive care in patients undergoing aggressive chemotherapy for acute myeloid leukemia (AML). As transfusion induces immune modulation, the objective of the study was to assess whether the …
View article: Fear of Recurrence and Somatic Symptom Severity in Multiple Myeloma Patients: An Institution-Based Cross-Sectional Study
Fear of Recurrence and Somatic Symptom Severity in Multiple Myeloma Patients: An Institution-Based Cross-Sectional Study Open
Introduction Psychosocial concerns especially fear of cancer recurrence (FCR) is less commonly addressed among patients with multiple myeloma in India. Myeloma being incurable, an understanding of this problem is essential for adequately a…
View article: The utility of day 14 bone marrow response assessment in patients undergoing acute myeloid leukemia induction
The utility of day 14 bone marrow response assessment in patients undergoing acute myeloid leukemia induction Open
Background: Examination of the bone marrow on day 14 of induction chemotherapy for acute myeloid leukemia (AML) is a common practice. However, the evidence for re-inducing the patient based on early bone marrow response is limited. Objecti…
View article: Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India
Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India Open
Introduction: Extranodal (EN) involvement in diffuse large B-cell lymphoma (DLBCL) carries poor prognosis. Both the number and the specific sites of EN involvement are important in predicting prognosis. Given that the epidemiologic pattern…
View article: Extent of transfusion support in a developing country in managing a bleeding acute myeloid leukemia patient with platelet transfusion refractoriness
Extent of transfusion support in a developing country in managing a bleeding acute myeloid leukemia patient with platelet transfusion refractoriness Open
Conventional platelet transfusion may not be adequate to deal with platelet transfusion refractoriness (PTR), and therefore human leukocyte antigen (HLA) or human platelet antigen (HPA) matched and platelet crossmatch compatible units are …
View article: Predictors of Survival in Children with Osteogenic Sarcoma Undergoing Limb Salvage Surgery: Experience from a Tertiary Cancer Center in Rural India
Predictors of Survival in Children with Osteogenic Sarcoma Undergoing Limb Salvage Surgery: Experience from a Tertiary Cancer Center in Rural India Open
Context: Osteogenic Sarcoma (OGS) is the fifth most common malignancy among adolescents aged 15–19. With multimodality therapy, the long-term survival has improved from 16% in the prechemotherapy era to around 70% in the postchemotherapy e…
View article: Gemcitabine, dexamethasone, and cisplatin salvage in relapsed lymphomas: A single institutional experience
Gemcitabine, dexamethasone, and cisplatin salvage in relapsed lymphomas: A single institutional experience Open
Introduction: Salvage chemotherapy followed by autologous stem cell transplantation is the standard of care in relapsed lymphoma. The optimal regimen for salvage is not defined. The combination of gemcitabine, dexamethasone, and cisplatin …
View article: Impact of early reduction in paraprotein on survival in transplant ineligible myeloma: Lesson from a tertiary cancer center in rural India
Impact of early reduction in paraprotein on survival in transplant ineligible myeloma: Lesson from a tertiary cancer center in rural India Open
Achieving a faster and deeper reduction in paraprotein as early as 3 months could lead to significant improvement in PFS.
View article: Health-related quality of life in patients with multiple myeloma on novel agents: Report from a tertiary cancer center in rural India
Health-related quality of life in patients with multiple myeloma on novel agents: Report from a tertiary cancer center in rural India Open
Background: Multiple myeloma is a disease where health-related quality of life (HRQoL) is an important treatment end point. There are limited quality of life data of patients on novel antimyeloma agents, especially from developing countrie…